Gabriella Marucci

Camerino, 62032, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 60 publications

Applying Deep-Learning-Driven De Novo Design to Hit Identification: A Case Study on A2A Adenosine Receptor Antagonists.

Applying Deep-Learning-Driven De Novo Design to Hit Identification: A Case Study on A2A Adenosine Receptor Antagonists.

Journal: Journal of medicinal chemistry

Published: June 19, 2026

Benzamide derivatives as allosteric ligands of the human and rat P2X7 receptor.

Benzamide derivatives as allosteric ligands of the human and rat P2X7 receptor.

Journal: Purinergic signalling

Published: February 10, 2026

A Holistic Approach to Identifying a Positron Emission Tomography (PET) Tracer Candidate for In Vivo Imaging of Purinergic P2X7 Receptor in Neuroinflammation.

A Holistic Approach to Identifying a Positron Emission Tomography (PET) Tracer Candidate for In Vivo Imaging of Purinergic P2X7 Receptor in Neuroinflammation.

Journal: ACS pharmacology & translational science

Published: December 23, 2025

Synthesis and characterization of new P2X7 receptor antagonists as antitumor agents.

Synthesis and characterization of new P2X7 receptor antagonists as antitumor agents.

Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

Published: December 02, 2025

Adenine nucleotides as potent and selective GPR17 modulators.

Adenine nucleotides as potent and selective GPR17 modulators.

Journal: Bioorganic chemistry

Published: November 03, 2025

8-Amino-1,2,4-triazolo[4,3-a]pyrazin-3-one derivatives hybridized with antioxidants: new highly potent and selective human A2A adenosine receptor antagonists as useful agents against cerebral ischemia.

8-Amino-1,2,4-triazolo[4,3-a]pyrazin-3-one derivatives hybridized with antioxidants: new highly potent and selective human A2A adenosine receptor antagonists as useful agents against cerebral ischemia.

Journal: Bioorganic chemistry

Published: June 18, 2025

Dissecting the tRNA Fragment tRF3E-Nucleolin Interaction: Implications in Breast Cancer.

Dissecting the tRNA Fragment tRF3E-Nucleolin Interaction: Implications in Breast Cancer.

Journal: Biomolecules

Published: June 10, 2025

Radioligands Targeting the Purinergic P2X Receptors.

Radioligands Targeting the Purinergic P2X Receptors.

Journal: Cells

Published: June 05, 2025

Beyond purinergic signaling: Dual ligand approaches to multitarget drug discovery.

Beyond purinergic signaling: Dual ligand approaches to multitarget drug discovery.

Journal: Drug discovery today

Published: May 22, 2025

Comparative analysis of the antiglioblastoma activity of adenosine A2A receptor and CK1δ blockers.

Comparative analysis of the antiglioblastoma activity of adenosine A2A receptor and CK1δ blockers.

Journal: European journal of pharmacology

Published: March 17, 2025

A2A Adenosine Receptor Antagonists and Their Efficacy in Rat Models of Parkinson's Disease.

A2A Adenosine Receptor Antagonists and Their Efficacy in Rat Models of Parkinson's Disease.

Journal: Cells

Published: December 30, 2024

A2A receptor antagonist 4-(2-((6-Amino-9-ethyl-8-(furan-2-yl)-9H-purin-2-yl)amino)ethyl)phenol, a promising adenosine derivative for glioblastoma treatment.

A2A receptor antagonist 4-(2-((6-Amino-9-ethyl-8-(furan-2-yl)-9H-purin-2-yl)amino)ethyl)phenol, a promising adenosine derivative for glioblastoma treatment.

Journal: European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences

Published: December 28, 2024

Showing 1-12 of 60

Last Updated: 09/26/2026